{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/0185cea5-9e3b-4b82-a887-26f91f92765f/ac8e9f7f-3644-41b1-a161-9c5ac6b44e78?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Audio long-read: How drugmakers can be better prepared for the next pandemic","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/61b9f3b71a8cbe675f3cedcb/61b9f40a7701000015817e21.jpg?height=200","description":"<p>Despite warnings, and a number of close calls, drugmakers failed to develop and stockpile drugs to fight a viral pandemic. Now, in the wake of SARS-CoV-2, they are pledging not to make the same mistake again.</p><p><br></p><p>Around the world, researchers are racing to develop drugs to target COVID-19, but also broad-spectrum antivirals that could be used to treat future viral threats.</p><p><br></p><p>This is an audio version of our feature: <a href=\"https://www.nature.com/articles/d41586-021-00958-4\" rel=\"noopener noreferrer\" target=\"_blank\">The race for antiviral drugs to beat COVID — and the next pandemic</a></p>","author_name":"Springer Nature Limited"}